Jim Cramer Stock Picks: Summit Therapeutics Is A 'Great Spec' - Carvana (NYSE:CVNA)
Carvana reported Q2 revenue of $7.38B, above $6.91B estimates, and EPS of 42 cents vs 36 cents, according to Benzinga Pro. Jim Cramer highlighted Summit Therapeutics as a “great spec” after it reported a smaller-than-expected Q2 loss but said it lacks working capital for 12 months. He also discussed Forgent Power, NVE, and Reddit.

